The risk or severity of adverse effects can be increased when Olanzapine is combined with Piritramide. The risk or severity of adverse effects can be increased when Estazolam is combined with Olanzapine. The therapeutic efficacy of Glipizide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Aripiprazole. Olanzapine may increase the QTc-prolonging activities of Ceritinib. Olanzapine may increase the QTc-prolonging activities of Anagrelide. Olanzapine may increase the QTc-prolonging activities of Ofloxacin. Olanzapine may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Risperidone. The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Olanzapine. Olanzapine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. The therapeutic efficacy of Apomorphine can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tolcapone. Olanzapine may increase the QTc-prolonging activities of Cisapride. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Olanzapine. Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The serum concentration of Erlotinib can be decreased when it is combined with Olanzapine. Alaproclate may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ezogabine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine. Olanzapine may increase the QTc-prolonging activities of Amiodarone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ecopipam. Iproniazid may increase the serotonergic activities of Olanzapine. The metabolism of Olanzapine can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Articaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levetiracetam. The risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine. Olanzapine may decrease the stimulatory activities of Amphetamine. The metabolism of Olanzapine can be decreased when combined with Rucaparib. The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Difenoxin. The serum concentration of Olanzapine can be increased when it is combined with Vemurafenib. The risk or severity of adverse effects can be increased when Ergotamine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Butamben. The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine. Phenoxypropazine may increase the serotonergic activities of Olanzapine. The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Thiamylal. The risk or severity of adverse effects can be increased when Olanzapine is combined with Scopolamine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrahydropalmatine. Olanzapine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. Lithium may increase the neurotoxic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with 7-Nitroindazole. The therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Lorcaserin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Agomelatine. Olanzapine may increase the QTc-prolonging activities of Citalopram. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. The risk or severity of adverse effects can be increased when Eletriptan is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Lumefantrine. Olanzapine may increase the QTc-prolonging activities of Dronedarone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Mepivacaine. The risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine. The therapeutic efficacy of Gliquidone can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Voglibose can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Sulfisoxazole. The metabolism of Olanzapine can be decreased when combined with Cocaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Guanfacine. The risk or severity of adverse effects can be increased when Codeine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ketobemidone. Olanzapine may increase the QTc-prolonging activities of Ondansetron. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrodotoxin. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. The risk or severity of adverse effects can be increased when Frovatriptan is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Ticlopidine. The therapeutic efficacy of Miglitol can be decreased when used in combination with Olanzapine. Levomilnacipran may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Lormetazepam is combined with Olanzapine. Olanzapine may decrease the stimulatory activities of Mephedrone. The serum concentration of Atazanavir can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Alprazolam is combined with Olanzapine. The serum concentration of Olanzapine can be decreased when it is combined with Valproic Acid. The therapeutic efficacy of Glyburide can be decreased when used in combination with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Bupropion. The risk or severity of adverse effects can be increased when Olanzapine is combined with Norflurane. The serum concentration of Fluvastatin can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pipamperone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Flibanserin. The risk or severity of adverse effects can be increased when Lorazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Brotizolam. The therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etifoxine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethotoin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxprenolol. Perampanel may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tiapride. Olanzapine may increase the QTc-prolonging activities of Toremifene. The risk or severity of adverse effects can be increased when Olanzapine is combined with Zaleplon. The risk or severity of adverse effects can be increased when Olanzapine is combined with Enflurane. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine. Olanzapine may increase the QTc-prolonging activities of Asenapine. Benmoxin may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dimenhydrinate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fluticasone propionate. The risk or severity of adverse effects can be increased when Nicergoline is combined with Olanzapine. Droperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Moxifloxacin. The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloral hydrate. The risk or severity of adverse effects can be increased when Procarbazine is combined with Olanzapine. The therapeutic efficacy of Liraglutide can be decreased when used in combination with Olanzapine. Olanzapine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy. Nabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levorphanol. The therapeutic efficacy of Olanzapine can be increased when used in combination with Pregabalin. The risk or severity of adverse effects can be increased when Propericiazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Entacapone. Olanzapine may increase the QTc-prolonging activities of Vandetanib. The serum concentration of Olanzapine can be increased when it is combined with Cobicistat. Iproclozide may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Doxepin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methadyl Acetate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Sepranolone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl loflazepate. Olanzapine may increase the QTc-prolonging activities of Telavancin. Olanzapine may increase the QTc-prolonging activities of Paliperidone. Olanzapine may increase the QTc-prolonging activities of Propafenone. The serum concentration of Lovastatin can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Midazolam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine. Toloxatone may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Moclobemide is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fencamfamine. The serum concentration of Gefitinib can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olanzapine.